General description
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 2J2 is a ZooMAb® rabbit recombinant monoclonal antibody that detects KDM5A. It targets an epitope within 21 amino acids from the C-terminal half.
Immunogen
KLH-conjugated linear peptide corresponding to 21 amino acids from the C-terminal half of human KDM5A.
Application
Quality Control Testing
Evaluated by Western Blotting in HeLa cell lysate.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected KDM5A in HeLa cell lysate.
Tested Applications
Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected KDM5A in lysate from HDLM-2 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected KDM5A in human prostate and breast cancer tissue sections.
Affinity Binding Assay: A representative lot of this antibody bound with KDM5A peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Lysine-specific demethylase 5A (UniProt: P29375; also known as EC:1.14.11.67, Histone demethylase JARID1A, Jumonji/ARID domain-containing protein 1A, Retinoblastoma-binding protein 2 (RBBP-2), [histone H3]-trimethyl-L-lysine(4) demethylase 5A) is encoded by the KDM5A (also known as JARID1A, RBBP2, RBP2) gene (Gene ID: 5927) in human. KDM5A is an epigenetic regulator, a member of the KDM5 family of proteins, which are known for their role in histone demethylation. KDM5A contains several functional domains, including a JmjC domain (aa 437-603) that is critical for its demethylase activity, allowing it to remove methyl groups from specific lysine residues on histone proteins. It also has PHD domains that can recognize methylated histones, contributing to its regulatory functions in chromatin. KDM5A specifically targets di- and tri-methylated lysine 4 on histone H3 (H3K4me2/3). By removing these methyl groups, KDM5A plays a crucial role in regulating gene expression, promoting transcriptional repression. It is involved in various cellular processes, including cell differentiation, proliferation, and stress responses. KDM5A is expressed in various tissues, with higher levels typically found in embryonic stem cells and certain cancer cells. Its expression can be influenced by developmental signals and environmental factors, reflecting its role in stem cell maintenance and differentiation. KDM5A has been implicated in several diseases, particularly cancer. Aberrant expression or mutations of KDM5A can lead to dysregulation of gene expression, contributing to tumorigenesis. It has been associated with various cancer types, including breast, lung, and prostate cancers. Additionally, KDM5A may play a role in other conditions, such as developmental disorders and neurodegenerative diseases. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Kirtana, R., et al., (2020), Exp Cell Res, 396, 112314)
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.